{"efta_number": "EFTA02351022", "page_count": 3, "url": "https://epstein-data.com/EFTA02351022", "pdf_url": "https://epstein-data.com/pdf/EFTA02351022.pdf", "pages": [{"efta_number": "EFTA02351022", "page_number": 0, "text_content": "From: \nMisha Gromov \nSent: \nSunday, May 15, 2016 8:25 AM \nTo: \nJeffrey E. \nSubject: \nRe: \n50/50 is generous; also will make me more involved if you ta=e it. \nthe erson I s oke to is Victoria Nik=forova \nbelow is the (rather long) summary/advertisement she sent me=on my request \nWe plan to bring to the healthcare marke= what we call a HealthSpan Pass — an individual rec=mmendation (an \nindividually designed healthcare pathway) on molecular adju=tments for healthy ageing and healthspan extension, \nbased on simultaneous =nalysis of near all molecules (comprising a human metabolome) in a microsa=ple of blood by \nmetabolomics approach being imposed on our academic expert-se in molecular metabolism of ageing. \nIn the production workflow we utilise bl=od metabolomics technology for identification of the molecular changes \nass=ciated with ageing and biomarkers of age-related disorders. Current and pa=t medicinal interventions, individual \nlifestyle habits and dietary prefere=ces are also reflected in a molecular composition of blood as a universal =etabolic \ninformation integrator. From such analysis imposed on our know-wh= on human molecular metabolism, we are able to \ndetermine the impact of par=icular metabolites on the developmental trajectory of healthy agei=g, to diagnose pre-\npathological healthspan violations and to indi=ate the precise molecular targets for personalised fine tuning of ageing \nmetabolism. Additionally, to expand availability of our ser=ice and to make it distance-independent, we plan to develop \na self=sampling device compatible with our technological metabolomics pl=tform, and to bring it to a medical self-care \nmarket as a valuable side pr=duct. \nIn the developmental process of our main=product HealthSpan Pass, two more add-value side products will be \ncreated:=UniMetaMarker (universal metabolic biomarker panel) and c=trong>AgeMetaMarker (healthspan metabolic \nbiomarker panel). A bio=arker panel is a set of molecules, selected from human metabolome, with in=icative diagnostic \nproperties and a synergistic prognostic power (over an =ndividual biomarker molecule). Our biomarker panels will be \nutilised for d=ug discovery, with special emphasis on metabolic disorders. Being particul=rly targeted on drug discovery \nfor age-associated diseasesatherosclerosis and cardiovascu=ar disease, cancer, arthritis, osteoporosis, type 2 diabetes, \nhypertension= Alzheimer's disease and Parkinson's disease, and further aim R&a=p;D at improved mechanisms of \ncontrolling and combating age-related chroni= and metabolic diseases through identification of novel drug targe=s \namong the involved molecules. We expect high demand for both bi=marker panels - the UniMetaMarker and the \nAgeMetaMarker - from pharma industry involved in drug development, and sp=cial interest to the AgeMetaMarker from \nthose on ageing-r=lated market. Results of our research and development of the UniMetaMarker=and the \nAgeMetaMarker will be utilised in designing of our main product, t=e HealthSpan Pass - a personalised recommendation \nfor fine tuning of metab=lism, based on detection of metabolic alterations critical for healthspan =n an individual \nmetabolome. \nEFTA_R1_01329057 \nEFTA02351022\n", "char_count": 3220}, {"efta_number": "EFTA02351022", "page_number": 1, "text_content": "Global health policy disposition. We are goin= to develop a product for individualised care, which does not exist \nyet on=the market, although there will definitely be a demand for it in line with=the Precision Medicine \n Initiative of the National Institutes of Health \n(USA) a=d the Smart Care=/a> project (EU). Ac=ording to NIH, \"Precision medicine is an emerging approach for disea=e \ntreatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each \nperson&rdquo=. The Smart Care Project piloted in the first ten EU regions also aims at =he individual care to be \ndelivered to older European citi=ens, with special emphasis on combating threats to independent living and =n self-care \nsupport. World Health Organization (WHO) in its last year Metanomics Health \nG=bH ), are =oncentrated mainly around \nlarge-scale analytics for pharma industry. As di=tinct from Metabolon, we from the very beginning aim our business at \nrouti=izing diagnostic metabolomics for personalised health care, and go ahead b= offering a prognostic metabolomics \nproduct for individual health improvem=nt sharpened at ageing and healthspan extension. So, current market \ndispos=tion makes our product unique and targeted at near future of healthcare in=ustry. \nBeing with our intended HealthSpan Pass =roduct a half-step ahead of the market, we plan fast busi=ess growth. \nElaborated business development model implies attainment of pr=jected HealthSpan Pass production in a timeframe of \n18 to 30 month= by the force of 10 to 14 business workers, depe=ding on raised financing. For a quick launch, we have \nass=mbled a highly qualified start-up team with German academic (Max Planck So=iety) and industrial (BASF) biomedical \ninnovation expertise. \nWe plan parallel growth of our busine=s in four main infrastructure directions: \nResearch & Development of biological markers; two biomark=r panels will be developed: UniMetaMarker \n(universal meta=olic biomarker panel as an add-value side product) and AgeMetaMark=r (healthspan metabolic \nbiomarker panel) \nTechnology development — most investment intens=ve (IP-reach, detailization provided by request), implies:=/p> \n- asse=bly of metabolite profiling machinery, and \n- tech=ical development of the device compatible with profiling machinery for sel= blood collection \nBusiness development (product support program provided by req=est) \nHealthSpan Pass — development of workflow & product=on \nWith the HealthSpan Pass we dare to d=fine 'Healthy Ageing - Happy Living' as our mission. \n2 \nEFTA_R1_01329058 \nEFTA02351023\n", "char_count": 2789}, {"efta_number": "EFTA02351022", "page_number": 2, "text_content": "On Fri, 13 May 2016 22:36:14 +0200, jeffrey E. wrote: \n1. always , if i invest in somethi=g you bring to me. the deal is the same for all my friends. &nb=p; I put up all \nthe money, take all the financial risk ,=and if there is a profit you and i split it 50/50. \n2. I , wrestling with , meaning in a musical phrase. /&nbs=; notes with out a relationship to each other . \n&nb=p; is composition the arrow on the note category.. = can we tell if the string is melodic. does the information \nin=the string somehow give us a window.? repetition. relati=n. temporal. , absolute number bounds. ? &nbs=; max \nnotes per sec? \n3. in your meaning re shape same issue. when i= round , round. coarse grain? etc. it appears to m= that if \nsomething has meaning , that something is bounded. &nb=p; . \nplease note \nThe information contained in this communication is \nconfidential, =ay be attorney-client privileged, may \nconstitute inside information, =nd is intended only for \nthe use of the addressee. It is the property =f \nTEE \nUnauthorized use, disclosure or copying of this \ncommu=ication or any part thereof is strictly prohibited \nand may be unlawfu=. If you have received this \ncommunication in error, please notify us =mmediately by \nreturn e-mail or by e-mail to jeevacation@gmail.com , and \ndestroy this communicat=on and all copies thereof, \nincluding all attachments. copyright -all =ights reserved \n3 \nEFTA_R1_01329059 \nEFTA02351024\n", "char_count": 1464}]}